What side effects are associated with this type of intervention?

Common treatments for artificial respiration, such as mechanical ventilation and spontaneous awakening/breathing trials, can have several side effects. These include ventilator-associated pneumonia, lung injury due to overdistension (barotrauma), decreased cardiac output, and muscle weakness due to prolonged immobility. Additionally, patients may experience anxiety and discomfort during the weaning process. Telehealth-enabled support aims to enhance coordination and monitoring, potentially mitigating some of these side effects by providing real-time feedback and more personalized care.

What prior FDA approvals exist?

The FDA has approved various treatments and devices aimed at improving outcomes for patients requiring artificial respiration. These include mechanical ventilators, which provide critical respiratory support, and adjunctive therapies such as phrenic nerve stimulators and diaphragm pacing systems. These devices help in maintaining respiratory function in patients with conditions like amyotrophic lateral sclerosis (ALS) and congenital central hypoventilation syndrome. Additionally, nonventilatory treatments and telehealth-enabled support systems are being explored to enhance the coordination and monitoring of spontaneous awakening and breathing trials, aiming to improve patient outcomes and reduce the duration of mechanical ventilation.

What other types of research exist?

Promising alternatives to Telehealth-Enabled Support for artificial respiration patients include: 1) Noninvasive ventilatory support, which provides respiratory assistance without the need for intubation, improving patient comfort and reducing complications. 2) Home sleep apnea testing (HSAT) with auto-CPAP titration, which offers a convenient and effective way to diagnose and manage sleep apnea, potentially reducing the need for in-laboratory testing. 3) Diaphragm pacing, which stimulates the diaphragm to improve respiratory function, particularly beneficial for patients with conditions like spinal cord injury or amyotrophic lateral sclerosis (ALS).

← Back to Search

Telehealth Support for Artificial Respiration (TEACH Trial)

N/A

Recruiting

Led By Colin Grissom, MD

Research Sponsored by Intermountain Health Care, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patient age must be greater than or equal to 16 years and admitted to study hospital ICU

Patient must be intubated and mechanically ventilated

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 28 days

Awards & highlights

Summary

This trial is testing a telehealth system called 'TEACH' to help doctors and nurses better manage the process of waking up and helping patients on ventilators breathe on their own. The goal is to improve patient outcomes by making it easier for healthcare providers to follow best practices.

Who is the study for?

This trial is for patients aged 16 or older who are in the ICU and on artificial breathing support. It's not for those who passed away within a day of being put on a ventilator or were already brain dead when admitted for organ donation.

What is being tested?

The study is testing if adding telehealth support to regular check-ups improves how well clinicians stick to protocols for waking up and breathing trials, which could lead to better outcomes for patients on ventilators.

What are the potential side effects?

Since this trial involves procedural changes rather than medications, traditional side effects aren't expected. However, there may be risks associated with changing the usual care process.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 16 or older and currently in the ICU of the study hospital.

Select...

I am on a breathing machine.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 28 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~28 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Adherence to C-SAT/SBT

Ventilator-free days to day 28

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention - Telehealth- enabled support plus usual audit and feedback for SAT/SBT adherenceExperimental Treatment2 Interventions

Usual audit and feedback + telehealth-enabled support

Group II: Control - Usual audit/feedback for SAT/SBT adherence onlyActive Control1 Intervention

Usual audit and feedback

0 / 2Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for artificial respiration include mechanical ventilation and spontaneous breathing trials (SBTs). Mechanical ventilation supports patients by delivering controlled breaths to maintain adequate oxygenation and carbon dioxide removal. SBTs assess a patient's ability to breathe independently by temporarily reducing or stopping ventilatory support. Telehealth-enabled support enhances these treatments by providing real-time monitoring and feedback, ensuring timely adjustments and coordination of care. This approach is crucial for improving patient outcomes, reducing the duration of mechanical ventilation, and facilitating safer and more efficient weaning processes.

Is servoventilation in central sleep apnea syndrom still working?.